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Introduction 
 
The purpose of this rapid review is to provide NHSScotland with advice on assessment 
of patients with COVID-19 in primary care. 
This guidance is for: general practitioners and primary care teams involved in the 
assessment of patients presenting with potential COVID-19. 
Since the outbreak of coronavirus, there has been an abundance of rapid and systematic 
reviews published on the diagnosis and management of people with symptoms of severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known as  COVID-19, mostly from 
a secondary care (hospital) perspective. About 80% of people with COVID-19 have symptoms 
which have been described as mild (no pneumonia manifestations / hospitalisation) or 
asymptomatic.1 Others develop severe disease (defined as requiring admission to an intensive 
care unit (ICU)). The challenge for primary care practitioners is to identify and triage patients 
presenting with potential COVID-19, a disease in which the pattern and duration of symptoms 
is heterogeneous. This is compounded by the need to conduct consultations via telephone or 
video. In addition, the evidence base is not robust and is subject to change as new evidence 
emerges.  
The COVID-19 Scottish Primary Care Hub Triage Guide lists the common symptoms, and 
provides red flags for those requiring immediate assessment and yellow flags for those at a 
higher risk of deterioration (eg certain comorbidities). We conducted a search for new 
evidence on prognostic indicators, risk factors and clinical measures to identify people self-
managing symptoms of COVID-19 in the community whose symptoms may change or worsen, 
and therefore may require monitoring or clinical intervention after their initial presentation to 
primary care. The research question and methodology can be found in section 6. 
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KEY FINDINGS 
 
Primary care clinicians should consider using the COVID-19 Scottish Primary Care Hub 
Triage Guide to inform initial consultations with patients presenting with potential COVID-19. 
Symptoms, characteristics, comorbidities and clinical signs in adults which may indicate a 
higher risk of progression to severe disease: 
 
 The only symptom identified which may distinguish severe disease is shortness of 
breath/dyspnoea. Some patients with hypoxia may not experience shortness of breath. 
(Table 1) 
 
 Characteristics which have been associated with severe disease are older age, male 
sex and minority ethnic background. Older age is the strongest predictor. (Table 2)  
 
 Comorbidities/risk factors most associated with severe disease are smoking, 
hypertension, cardiovascular disease, diabetes, obesity, stroke, chronic pulmonary 
disease, chronic kidney disease, cancer and solid organ transplantation. (Table 2)   
 
 Rheumatoid arthritis, psoriatic arthritis, lupus and other immunosuppressive conditions 
are significantly associated with severe disease. There was mixed evidence of any 
association between steroids, use of immunosuppressant medication, angiotensin-
converting enzyme (ACE) inhibitors or angiotensin II receptor (AT1) antagonists and 
severe COVID-19 disease but very few studies have investigated this. (Table 2) 
 
 The evidence for chronic liver disease as a risk factor is mixed. 
 
 Some evidence is emerging that less advantaged socioeconomic status and frailty are 
associated with poor outcomes. (Table 2) 
 
 Clinical signs which have been found to be associated with severe disease are low 
oxygen saturation levels, low blood pressure and high respiratory rate. Of these, the 
strongest evidence relates to oxygen saturation levels. (Table 3) 
 
 The evidence base remains too weak and emergent to make definitive 
recommendations. 
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1. Signs and symptoms 
The intention of this evidence review was to identify any evidence of symptoms in adults which 
may differ between mild, moderate and severe disease. The initial scoping of the evidence 
identified a COVID-19 signs and symptoms tracker which presents severe and non-severe 
symptoms based on early data from China, https://www.cebm.net/covid-19/covid-19-signs-
and-symptoms-tracker/. This was produced by The Centre for Evidence-Based Medicine at 
the University of Oxford and was based on an unpublished systematic review and meta-
analysis.2 Unpublished studies have not been subject to peer review. We identified a published 
systematic review and meta-analysis which included 43 studies and 3,600 patients mostly 
from China.3 Details of the prevalence of symptoms found in this study are given in Table 1. 
A review, which includes data from the United Kingdom, found little evidence to differentiate 
between mild and moderate symptoms and those in a severe condition.1   
Our initial rapid review (see section 6) identified a mixture of published studies and preprints 
or preliminary reports that included data on signs and symptoms from mixed healthcare 
settings, primarily in the United States (US) and Italy. Most studies are retrospective, 
observational studies so are potentially biased and may not be easily generalisable to Scottish 
primary care practice.  Preprint studies have not been subject to peer review. The update is 
primarily based on published studies and some of the preprint papers from the initial review 
that have since been published.  However, some of the evidence used is from preprint 
sources. For these reasons, all evidence reported should be considered low quality and needs 
to be interpreted with caution. Table 1 includes the results of the review of published and 
preprint literature comparing symptoms of mild/moderate and severe disease from settings 
other than China. It compares them to the findings from a systematic review of 43 studies and 
3,600 patients mostly from China.3 In Table 1 the symptoms listed are those which have been 
identified as associated with COVID-19. For some symptoms we found no evidence 
comparing that symptom in cases of mild/moderate and severe disease. This is noted in Table 
1. It is not always clear in the literature how the authors define severe disease. For the 
purposes of this review we considered that disease was severe when a patient was admitted 
to ICU. In Table 1 ‘all cases’ means all diagnosed cases and may include mild, moderate and 
severe disease. The severity of disease as a percentage of the diagnosed cases would be 
likely to vary depending on the testing policy in place in that setting at the time the data was 
collected. This may also result in a higher percentage of confirmed cases in subgroups 
believed to be at risk as they are more likely to have been tested.  
The Chinese meta-analysis provides weak evidence that dyspnoea may be an indicator of 
severe disease as 49% of patients with severe disease experienced dyspnoea compared to 
13% of patients with non-severe disease.3 This finding is supported by evidence from outside 
China where 21 out of 24  patients (88%) in ICU in the US4 experienced shortness of breath 
compared with 5% of the first 38 diagnosed cases (of any severity) from eight European 
countries5 and 32% of cases confirmed after presenting at an Emergency Department in Italy.6  
There is some evidence that patients may be suffering from hypoxia without showing outward 
symptoms of shortness of breath.7 
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  Table 1: Prevalence of symptoms in mild/moderate and severe COVID-19 
Symptoms 
associated with 
COVID-19 
Prevalence (% of cases - range) 
from studies outside China 
Prevalence (% of cases) 
from meta-analysis – 
mainly China3 
 ICU Hospitalised 
patients 
All 
cases 
Critical 
illness 
Non-critical 
illness 
Cough4-6,8-10 88 66–86 16–37 66 57 
Fever >37.8oC5,6,8,10-
13  
28–73 24–85 20–84 81 71 
Dyspnoea4-6,8,10,14 88 11–80 5–32 49 13 
Fatigue5,11 - 33 21 42 34 
Cough (sputum) No evidence found comparing 
mild/moderate to severe disease  
 
 
32 31 
Delirium (confusion) No evidence found comparing mild/moderate to severe disease. 
Diarrhoea8,11 - 17–27 - 8 4 
Vomiting/nausea6,8,11  - 8–24 8 - - 
Myalgia8,11,14 - 34–42 16 18 21 
Chest pain6,9,14  - - 2–4 - - 
Anosmia/dysgeusia No evidence found comparing mild/moderate to severe disease  
Headache4-6,11 8 17 2–16 11 12 
Dizziness No evidence found comparing mild/moderate to severe disease  
Abdominal pain6,11 - 17 1 - - 
Sore throat4-6,8-11,14  8 18–61 1–8 17 11 
 
2. Prognostic Tools 
A variety of risk prediction scores and tools have been developed, which may have use in the 
community. Further research is required for validation and to determine which would be most 
appropriate in a community setting. A summary is available here: https://www.cebm.net/covid-
19/what-clinical-features-or-scoring-system-if-any-might-best-predict-a-benefit-from-hospital-
admission-for-patients-with-covid-19/  
As yet, no trials have been conducted to validate the use of the National Early Warning Score 
(NEWS) or NEWS 2 in the assessment of patients for COVID-19 in primary care.15 However, 
it has been temporarily endorsed by the Royal College of General Practitioners as a response 
to COVID-19 https://elearning.rcgp.org.uk/mod/page/view.php?id=10570 
Five studies of association between comorbidities or risk factors and hospitalisation for 
COVID-19, severe illness or death were identified.6,12,13,16 Table 2 shows the associations 
noted in these studies as well as ranges of comorbidities/risk factors identified from the wider 
body of identified studies. A meta-analysis, available as a preprint, summarises findings of 63 
association studies of which 57 were from China.17 Relevant information from this study is also 
provided in Table 2. Not all variables are included in all studies and considerable risks of 
confounding remain, which may explain the variation in the results reported in these studies. 
The headings used for the comorbidities/risk factors are those cited in the studies and have 
not been recategorised for this review. 
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Table 2: Comorbidities and risk factors associated with COVID-19 
Comorbidity/risk factor 
Age  
 
Older age 
significantly 
associated with 
severe disease. 
 
 
Older age was reported as significantly associated with severe 
disease in 47 out of 54 studies (87%) in an unpublished meta-
analysis including 17,648 patients with COVID-19, mostly in 
China.17    
 
The average age for hospitalisation reported in studies from the 
US and Italy was 53–68 years, for ICU admission was 63–70 years 
and for death was 77–81 years.4,6,12,13,18-23 
 
A recent large observational study of 10,926 COVID-19 deaths in 
England found that COVID-19 death was significantly associated 
with older age. The hazard ratio (HR) (compared with age 50–59) 
for age ≥80 was 20.6 (18.7 to 22.7), 70–79 was 6.1 (5.5 to 6.7) and 
60–69 was 2.4 (2.2 to 2.7).24   
 
A study examining associations in 5,279 confirmed cases in New 
York found that older age was the strongest predictor of 
hospitalisation. Age ≥75 years (odds ratio (OR) 37.9, 95% 
confidence interval (CI) 26.1 to 56.0) and age 65–74 (OR 8.7, 95% 
CI 6.7 to 11.2). The association was retained albeit weakly for risk 
of critical illness after blood test results on admission were 
included in the analysis: age ≥75 years (OR 2.3, 95% CI 1.6 to 3.4) 
and age 65–74 (OR 1.7, 95% CI 1.2 to 2.5).12  
 
Other studies of association for settings outside China found mixed 
results. An unpublished study of 585 cases in US veterans aged 
54–75 found age significantly associated with hospitalisation but 
not ICU admission when laboratory findings were included in the 
analysis.13 An unpublished study of 2,653 cases in Italy found that 
age was significantly associated with both hospitalisation and 
death.16 A smaller unpublished Italian study of 411 cases found 
that older age was significantly associated with death but not 
admission to ICU.6 A small US study (n=54) found that older age 
was significantly associated with hospital admission and 
pneumonia but not if oxygen saturation levels were included in the 
analysis.23 
 
Sex  
 
Male sex  
significantly 
associated with 
severe disease. 
Male sex was reported as significantly associated with severe 
disease in 16 out of 45 studies (36%) which reported on sex in an 
unpublished meta-analysis including 17,648 patients with COVID-
19, mostly in China.17 
 
In studies from Korea, Europe, Italy, USA and Bolivia, males 
accounted for 38–67% of cases, 50–63% of hospital admissions, 
63–93% of severe disease and 56–74% of deaths.4,6,12,18-23 
 
A recent large observational study of 10,926 COVID-19 deaths in 
England found that COVID-19 death was significantly associated 
with male sex (HR 1.6, 95% CI 1.5 to 1.7).24  
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A study examining associations in 5,279 confirmed cases in New 
York found that there was a significant association between male 
sex and hospitalisation (OR 2.8, 95% CI 2.4 to 3.2) but not critical 
illness once laboratory results were included in the analysis.12 Two 
unpublished studies from settings outside China were identified. A 
study of 2,653 cases in Italy found that male sex was significantly 
associated with both hospitalisation and death.16 Another Italian 
study, of 411 cases at a single hospital, found that male sex was 
significantly associated with admission to ICU but not death.6 
 
Ethnicity  
 
Minority ethnic 
background 
significantly 
associated with 
severe disease. 
There is no mention of ethnicity as a variable of interest in an 
unpublished meta-analysis including 17,648 patients with COVID-
19, mostly in China.17  
 
A systematic review of ethnicity reporting in patients with COVID-
19 and its relation to clinical outcomes suggested that evidence on 
ethnicity as a risk factor for disease severity has emerged more 
slowly than clinical risk factors, in part because studies published 
in China do not report data disaggregated by ethnicity. Data from 
the grey literature and preprint articles suggest that those of Black 
and Asian ethnicities are at increased risk of hospitalisation, 
admission to the intensive care unit and death.25 
 
Two large UK observational studies (n=78,443 and n=34,986) 
provided evidence that a minority ethnic background, in particular 
South Asian ethnicity, was an independent risk factor for poor 
outcomes.26,27 Critical care admission was more common in South 
Asian (OR 1.28, 95% CI 1.09 to 1.52), Black (OR 1.36, 1.14 to 
1.62), and other minority ethnic groups (OR 1.29, 1.13 to 1.47) 
compared with the White group, after adjusting for age, sex and 
location.27  
 
A recent large observational study of 10,926 COVID-19 deaths in 
England found that COVID-19 death was significantly associated 
with Black (HR 1.5, 95% CI 1.3 to 1.7), South Asian (HR 1.4, 95% 
CI 1.3 to 1.6) and mixed ethnicity (HR 1.4, 95% CI 1.1 to 1.8) 
compared with White ethnicity. The associations were adjusted for 
comorbidity, age, sex but not adjusted for employment or housing 
density.24  
 
A study of 5,279 cases in New York found no significant 
association between Asian ethnicity and either hospitalisation (OR 
1.29, 95% CI 0.97 to 1.72) or critical illness (OR 1.24, 95% CI 0.82 
to 1.90). The same study also found no association between 
African American ethnicity and hospitalisation and a negative 
association with critical illness (ie African Americans were less 
likely to experience critical illness), OR 0.6, 95% CI 0.4 to 0.8.12 A 
further preprint study of 585 cases in a US cohort of veterans aged 
54–75 found that Black ethnicity was significantly associated with 
testing positive for COVID-19 but was not associated with 
hospitalisation or admission to intensive care.13 
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Socioeconomic 
status 
 
Significantly 
associated with poor 
outcomes 
A national audit of demographics, activity and outcomes for 
patients with laboratory-confirmed COVID-19 disease admitted to 
Scottish ICUs between 1 March and 20 June 2020 reported that a 
greater proportion of patients in the highest quintile of deprivation 
was admitted to ICU than patients in the lowest quintile (24.4% v 
16.2%). Overall estimated 30-day mortality for all patients admitted 
to ICU was 38.7%, with a higher estimate of death among those in 
the highest quintile of deprivation compared with those in the 
lowest quintile (48.7% v 34.7%).28 
 
In Scotland, the age-standardised rate of deaths involving COVID-
19 between 1 March 2020 and 30 June 2020 in the most deprived 
quintile (124.1 per 100,000 population) was 2.1 times higher than 
in the least deprived quintile (60.5 per 100,000 population).29 
 
A recent study using UK Biobank data found those living in the 
least advantaged quartile to be at greater risk of being tested, 
testing positive and testing positive in hospital.30 
 
Obesity  
 
Significantly 
associated with 
severe disease. 
Body mass index (BMI) was reported as significantly associated 
with severe disease in six out of 11 studies (55%) in an 
unpublished meta-analysis including 17,648 patients with COVID-
19, mostly in China.17 
 
A recent large observational study of 10,926 COVID-19 deaths in 
England found that COVID-19 death was significantly associated 
with obesity. The hazard ratio for BMI of 30–34.9 was 1.1 (95% CI 
1.0 to 1.1), 35–39.9 was 1.4 (95% CI 1.3 to 1.5) and 40 or over 
was 1.9 (95% CI 1.7 to 2.1) all compared with BMI <30 24 
 
One US study (n=5,279) found that obesity was one of the most 
important factors for hospitalisation after age; BMI >40 kg/m2 (OR 
2.5, 95% CI  1.8 to 3.4) and BMI 30-40 kg/m2 (OR 1.8, 95% CI 1.5 
to 2.2).12 BMI was also associated with critical illness in those with 
BMI >40 kg/m2 (OR 1.7, 95% CI 1.1 to 2.7) but not in those with 
BMI 30–40 kg/m2 (OR 1.1, 95% CI 0.85 to 1.5).12 An Italian study 
including 2,653 cases found that obesity was not associated with 
either hospitalisation or death.16  
 
Obesity may be particularly strongly associated with poorer 
outcomes in younger patients. Another study which included 3,615 
COVID-19–positive symptomatic patients presenting to an 
academic hospital in New York found that patients aged < 60 years 
with a BMI ≥35 were 2.2 (95% CI, 1.7 to 2.9) and 3.6 (95% CI, 2.5 
to 5.3) times more likely to be admitted to acute and critical care 
than patients in the same age category who had BMI < 30.31  
 
A further unpublished study in New York included 572 patients 
aged 50 or below and 2,843 patients aged over 50 with confirmed 
COVID-19. For the younger population, BMI above 40 kg/m2 was 
independently associated with mortality (adjusted OR 5.1, 95% CI 
2.3 to 11.1). For the older population, BMI above 40 kg/m2 was 
also independently associated with mortality to a lesser extent 
(adjusted OR 1.6, 95% CI 1.2 to 2.3).32 
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A small study carried out in several US hospitals found a 
significant inverse correlation between age and BMI, in which 
younger individuals admitted to hospital were more likely to be 
obese.33 
 
A prospective multicentre cohort study of 77 pregnant women with 
confirmed COVID-19 infection who were admitted to 12 Italian 
maternity hospitals reported that increased pregestational BMI was 
associated with severe disease.34   
 
Smoking  
 
Significantly 
associated with 
severe disease. 
A meta-analysis of 19 peer-reviewed papers showed that smoking 
is associated with disease progression and severe disease, with 
smokers having 1.91 times the odds of progression in COVID-19 
severity compared with people who never smoked.35 
 
A systematic review of peer-reviewed studies carried out by the 
World Health Organization (WHO) suggested that smoking is 
associated with increased severity of disease and death in 
hospitalised COVID-19 patients. The authors note that although 
likely related to severity, there is no evidence to quantify the risk to 
smokers of COVID-19-related hospitalisation.36 
 
A recent large observational study of 10,926 COVID-19 deaths in 
England found that COVID-19 death was significantly associated 
with former smoking (HR 1.2, 95% CI 1.1 to 1.2) but not current 
smoking (HR 0.9, 95% CI 0.8 to 1).24 
 
Being a current smoker was reported as significantly associated 
with severe disease in one out of 11 studies (9%) in the 
unpublished meta-analysis including 17,648 patients with COVID-
19, mostly in China.17 
 
In the association studies identified for settings outside China two 
studies considered smoking. One study of 585 cases in US 
veterans found no association with hospitalisation or ICU 
admission.13 A study of 5,279 cases in New York found a negative 
association between current smoking and hospitalisation (OR 0.59, 
95% CI 0.43 to 0.81) and former smoking and hospitalisation (OR 
0.69, 95% CI 0.56 to 0.85) but no association between either risk 
factor and critical illness.12 A systematic review including 28 
studies concluded that there was low-quality evidence that current 
and former smoking compared with never smoking is associated 
with greater disease severity.37 
 
Cancer  
 
Significantly 
associated with 
severe disease. 
Cancer was reported as significantly associated with severe 
disease in five out of 19 studies (26%) in an unpublished meta-
analysis including 17,648 COVID-19 patients, mostly in China.17 
 
Four of the association studies identified from settings outside 
China included cancer in their analysis. Three studies found no 
association with hospitalisation, admission to ICU or death.6,12,13  
One study of 2,653 cases in Italy found that cancer was associated 
with both hospitalisation (HR 1.4, 95% CI 1.1 to 1.7) and death 
(HR 1.4, 95% CI 1 to 2).16  
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A recent large observational study of 10,926 COVID-19 deaths in 
England distinguished haematological and non-haematological 
cancer and time since diagnosis. The study found that COVID-19 
death was significantly associated with both types of cancer. For 
recently diagnosed haematological cancer the HR was 2.8 (95% CI 
2.1 to 3.8) reducing to 1.6 (95% CI 1.4 to 1.9) if diagnosed more 
than 5 years previously. For non-haematological cancers the HR 
was 1.7 (95% CI 1.5 to 2) for cancer diagnosed within a year 
reducing to an equivalent risk as individuals without cancer for 
cancers diagnosed more than 5 years previously.24 
 
There is emerging evidence that the association between cancer 
and COVID-19 severity is more nuanced and cannot be described 
simply in the context of presence of cancer diagnosis alone. A 
prospective cohort study from the UK Coronavirus Cancer 
Monitoring Project which included 800 patients admitted to hospital 
over a 5-week period with a diagnosis of cancer and symptomatic 
COVID-19 reported that 226 patients (28%) died. Risk of death 
was significantly associated with older patient age (OR 9.42, 95% 
CI 6.56 to 10.02), male sex (OR 1.67, 95% CI 1.19 to 2.34) and the 
presence of other comorbidities such as hypertension (OR 1.95, 
95% CI 1.36 to 2.80) and cardiovascular disease (CVD) (OR 2.32, 
95% CI 1.47 to 3.64). After adjusting for age, gender, and 
comorbidities, chemotherapy in the previous 4 weeks was not 
significantly associated with mortality from COVID-19 disease 
compared with patients with cancer who had not received recent 
chemotherapy (OR 1.18, 95% CI 0.81 to 1.72). There was no 
significant effect on mortality for patients who received 
immunotherapy, hormonal therapy, targeted therapy or 
radiotherapy within the previous 4 weeks.38 
 
A further cohort study which included 928 patients with active or 
previous cancer and a confirmed diagnosis of COVID-19 in the 
USA, Canada and Spain reported independent association 
between the following factors and death (all odds ratios partially 
adjusted): increased age (per 10 years; OR 1.84, 95% CI 1.53 to 
2.21), male sex (OR 1.63, 95% CI 1.07 to 2.48), smoking status 
(former smoker v never smoked: 1.60, 95% CI 1.03 to 2.47), 
number of comorbidities (two v none: 4.50, 95% CI 1.33 to 15.28), 
active cancer (progressing v remission: 5.20, 95% CI 2.77 to 9.77), 
and receipt of azithromycin plus hydroxychloroquine (v treatment 
with neither: 2.93, 95% CI 1.79 to 4.79; authors note that 
confounding by indication cannot be excluded). Ethnicity, obesity, 
cancer type, type of anticancer therapy, and recent surgery were 
not associated with mortality.39   
 
Cardiovascular 
disease  
 
Significantly 
associated with 
severe disease. 
 
 
Cardiovascular disease 
Cardiovascular disease (CVD) was reported as significantly 
associated with severe disease in 16 out of 25 studies (64%) in a 
large unpublished meta-analysis of mostly Chinese studies.17 After 
age and ‘at least one comorbidity’, CVD and hypertension had the 
strongest association. 
 
An Italian study of 411 cases found CVD had a significant 
association with death but not with ICU admission.6  
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Hypertension 
Hypertension was reported as significantly associated with severe 
disease in 22 out of 33 studies (67%) and coronary vascular 
disease in 16 out of 25 studies (64%) in the large unpublished 
meta-analysis of mostly Chinese studies.17 After age and any 
comorbidity these two conditions had the strongest association. 
 
One study of 5,279 confirmed cases in New York found an 
association between hypertension and hospitalisation (OR 1.78, 
95% CI 1.49 to 2.12) but no association with critical illness.12 
 
A further US study (n=585) did not find any significant association 
between hypertension and hospitalisation or critical illness.12,13 
Two Italian studies (n=2,653 and n=411) found that hypertension 
was significantly associated with both hospitalisation and death.6,16 
A fifth study (n=54) found hypertension significant for 
hospitalisation and acute respiratory distress syndrome (ARDS) 
but that the significance disappeared if oxygen saturation was 
included in the analysis.23 
 
Stroke 
Stroke was also reported as significantly associated with severe 
disease in five out of 12 studies in the systematic review of 
Chinese studies (42%).17 
 
Heart failure 
One Italian (n=2,653) and one US study (n=5,279) found 
significant associations between heart failure and hospitalisation, 
critical illness or death.12,16 
 
Coronary artery disease 
A US study (n=5,279) found no association between coronary 
artery disease and hospitalisation or critical illness.12  
 
Ischaemic heart disease 
One Italian study (n=2,653) found a significant association 
between ischaemic heart disease and both hospitalisation and 
death.16 
 
Arrhythmia 
One Italian study (n=2,653) found a significant association 
between arrhythmia and both hospitalisation and death.16 
 
Vascular disease 
Two studies (Italy, n=2,653; US, n=585) found no associations 
between vascular disease and death.13,16 
 
Hyperlipidaemia 
One study (US, n=5,279) found hyperlipidaemia had a negative 
association with hospitalisation but found no association with 
critical illness.12 Another found no association between 
dyslipidaemia and hospitalisation or death.16 
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ACE inhibitors and AT1 antagonists 
Four of the association studies identified for settings outside China 
included ACE-I and AT1 antagonists in their analysis. Three 
studies found no association with either hospitalisation or severe 
disease.6,13,23 One study (Italy, n=2,653) found that the medication 
was associated with hospitalisation but not death.16 
 
A meta-analysis of nine studies involving 3,936 patients with 
hypertension found that use of ACE inhibitors and AT1 antagonists 
was not significantly associated with severe disease but was 
significantly associated with reduction in mortality, (OR 0.57, 95% 
CI 0.38 to 0.84).40 
  
Chronic kidney 
disease  
 
Significantly 
associated with 
severe disease. 
Chronic kidney disease (CKD) was reported as significantly 
associated with severe disease in four out of 14 studies (29%) in 
an unpublished meta-analysis including 17,648 COVID-19 
patients, mostly in China.17  
   
Four of the association studies identified from settings other than 
China included CKD in the analysis. All found some evidence of 
association with hospitalisation but the picture relating to severe 
disease and death was more mixed. A study of 5,279 confirmed 
cases in New York found that CKD had the strongest association 
with hospitalisation (OR 2.6, 95% CI 1.9 to 3.6) after age and heart 
failure but was inversely associated with critical illness (OR 0.73, 
95% CI 0.55 to 1.0). A study of 2,653 cases in Italy found that CKD 
was associated with hospitalisation (HR 1.9, 95% CI 1.3 to 2.9) but 
not death.16 A US study of 585 cases in veterans aged 54–75 
found a significant association for both hospitalisation and ICU 
admission in univariate analyses which was no longer significant 
when laboratory results were added to the analysis.13 An Italian 
study of 411 cases found renal insufficiency to be associated with 
both death and ICU admission.6 
 
Chronic liver 
disease  
 
Evidence of 
association is 
unclear. 
 
Hepatitis or cirrhosis was reported as significantly associated with 
severe disease in none of the 14 studies in an unpublished meta-
analysis including 17,648 COVID-19 patients, mostly in China.17  
However, a number of studies in China have shown an association 
between metabolic associated fatty liver disease and severe 
COVID-19 disease.41-43 
 
In contrast, a multicentre retrospective study (n=50) and a 
multicentre research network study (n=2,780) showed that chronic 
liver disease (particularly cirrhosis) was associated with severe 
disease in Italy and the US.44,45 
 
Chronic respiratory 
disease  
 
Significantly 
associated with 
severe disease. 
Chronic obstructive pulmonary disease (COPD) was reported as 
significantly associated with severe disease in six out of 19 studies 
(32%) which reported the variable in an unpublished meta-analysis 
including 17,648 COVID-19 patients, mostly in China.17 Other 
respiratory disease was reported as significantly associated with 
severe disease in two out of seven studies (29%) in the same 
meta-analysis. 
 
 
  
 
12 
 
A recent large observational study of 10,926 COVID-19 deaths in 
England found that COVID-19 death was significantly associated 
with respiratory disease (excluding asthma) (HR 1.6, 95% CI 1.5 to 
1.7). Asthma with recent oral corticosteroid use was significantly 
associated with COVID-19 death (HR 1.1, 95% CI 1.0 to 1.3) but in 
individuals with asthma without this use there was no significant 
association (HR 1, 95% CI 0.9 to 1).24 
 
In unpublished studies from Korea and the USA and one published 
study from the USA, the prevalence of chronic respiratory disease 
was 7–15% % in cases, 7–17% in hospital admissions, 11–21% in 
ICU admissions and 17% in patients who died.8,12,18,46  
 
Four of the association studies identified from settings other than 
China included pulmonary disease in their analysis. Results of the 
analysis were mixed. Two studies found no associations. A study 
of 5,279 confirmed cases in New York found no association 
between pulmonary disease and hospitalisation or critical illness.12 
A study of 411 cases from one hospital in Italy found pulmonary 
diseases not to be associated with death or admission to ICU.6 
Two studies (US, n=585; Italy n=2,653) found associations with 
hospitalisation but not severe disease or death.13,16  
 
The evidence for asthma as a risk factor for COVID-19 severity is 
mixed. A large population-based cohort study using data from the 
UK Biobank (n=492,768) reported that adults with asthma had a 
higher risk of severe COVID-19, which was driven by the increased 
risk in patients with non-allergic asthma (adjusted OR 1.48, 95% CI 
1.15 to 1.92). In contrast, the risk of severe COVID-19 was not 
significantly elevated in patients with allergic asthma.47 
 
A smaller US cohort study (n=935) indicated that asthma was 
associated with longer intubation time in hospitalised patients but 
not hospitalisation, intubation, duration of hospitalisation, ARDS or 
death.48 
 
No associations were found for asthma in the single study which 
looked at this separately.13   
 
Diabetes  
 
Significantly 
associated with 
severe disease. 
Diabetes was reported as significantly associated with severe 
disease in 13 out of 32 studies (41%) in the unpublished meta-
analysis including 17,648 COVID-19 patients, mostly in China.17 
 
An unpublished population cohort study assessing the risks of 
hospital death with COVID-19 between 1 March and 11 May 2020 
in individuals registered with a general practitioner in England 
included 263,830 people with a recorded diagnosis of Type 1 
diabetes and 2,864,670 people with a recorded diagnosis of Type 
2 diabetes. Adjusted for age, sex, deprivation, ethnicity and 
geographical region, people with Type 1 and Type 2 diabetes had 
3.50 (95% CI 3.15 to 3.89) and 2.03 (95% CI 1.97 to 2.09) times 
the odds, respectively, of dying in hospital with COVID-19 
compared with those without diabetes.49 
A further unpublished cohort study by the same authors showed 
that hyperglycaemia in people with Type 1 or Type 2 diabetes was 
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independently associated with increased COVID-19 mortality. Risk 
of death was significantly higher in those with an HbA1c >58 
mmol/mol and increased as HbA1c levels rose.50 
 
A US study with 5,279 cases found a significant association 
between diabetes and hospitalisation (OR 2.24, 95% CI (1.84 to 
2.73) but not critical illness.12 Another US study (n=585) found a 
significant association for hospitalisation but not critical illness.13 
An Italian study (n=2,653) found that diabetes was significantly 
associated with death but not admission to ICU.16   
 
Studies have demonstrated an association between a range of 
diabetes parameters (including admission blood glucose, glucose 
coefficient of variation, median blood glucose, median in-hospital 
glucose level, maximum blood glucose and minimum blood 
glucose) and disease severity and mortality in patients. 
Hyperglycaemia was an independent risk factor for progression to 
critical cases and/or death among non-critical cases.51,52 
 
An unpublished retrospective cohort study of 453 patients admitted 
to hospital with COVID-19 in Wuhan, China showed that patients 
with newly-diagnosed diabetes had the highest risk of all-cause 
mortality compared with patients with known diabetes, 
hyperglycaemia and normal glucose.53 
 
Frailty 
 
Significantly 
associated with 
death. 
A prospective observational study of 1,564 patients in 10 UK and 
one Italian hospital found that Clinical Frailty Scores (CFS) 5–6 
(mildly and moderately frail) and 7–9 (severe and very severe 
frailty or terminal illness) were significantly associated with 30-day 
mortality. Adjusted hazard ratios compared with a CFS score of 1–
2 (fit and well) were 1.8 (95% CI 1.5 to 2.9) for scores 5–6 and 2.4 
(95% CI 1.5 to 3.8) for scores 7–9.54 
 
Immunosuppressive 
conditions 
 
Significantly 
associated with death 
A recent large observational study of 10,926 COVID-19 deaths in 
England found that COVID-19 death was significantly associated 
with rheumatoid arthritis, psoriatic arthritis or lupus (HR 1.2, 95% 
CI 1.1 to 1.3) and other immunosuppressive conditions (HR 1.7, 
95% CI 1.3 to 2.2).24 
 
Solid organ 
transplants 
 
Significantly 
associated with 
death. 
A recent large observational study of 10,926 COVID-19 deaths in 
England found that COVID-19 death was significantly associated 
with organ transplant (HR 3.6, 95% CI 2.8 to 4.5) 24 
 
Other evidence on solid organ transplants as a risk factor for 
severe COVID-19 disease is mixed. A number of small case 
studies and cohort studies from China, the US and the UK have 
reported that individuals with solid organ transplants may be at 
higher risk of severe illness or complications, more rapid clinical 
progression, and a prolonged clinical course compared with the 
general population, due to chronic immunosuppression and the 
presence of co-existing conditions.55-58 In contrast, a US case 
series of 15 kidney transplant recipients reported outcomes similar 
to the general population.59 
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Steroids or other 
immuno-
suppressants  
 
Evidence of 
association is 
unclear.  
Immunocompromise was considered in only two out of 63 studies 
of association reported in an unpublished meta-analysis of 17,648 
COVID-19 cases, mostly in China.17 Neither of the studies found 
that it was significantly associated with severe disease.  
 
In two studies from the USA (n=2,026,227 and n=5,143) patients 
on immunosuppressant medications accounted for 3–5% of cases, 
6% of hospital admissions and 6–9% of severe disease.13,46  
 
None of the identified association studies from settings outside 
China included steroids or immunosuppressants in the 
analysis.6,12,13,16,23  
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At least one 
comorbidity  
 
Associated with 
severe disease. 
At least one comorbidity was reported as significantly associated 
with severe disease in 17 out of 23 (74%) studies which reported 
the variable in an unpublished meta-analysis including 17, 648 
COVID-19 patients, mostly in China.17  It was second only to age 
as the variable which was reported as significant in the highest 
percentage of studies.    
    
In studies from Singapore, Korea, Italy and USA patients reported 
as having at least one comorbidity accounted for 27–29% of cases, 
71–89% of hospital admissions, 68–78% of severe disease and 
95–99% of deaths.4,6,12,18-23  
 
Only one of the identified association studies included ‘at least one 
comorbidity’ as a variable. Three other studies looked only at 
individual comorbidities12,13,23 and one used a composite score of 
comorbidity, the Charlson Comorbidity Index.16 A study of 411 
cases presenting at an emergency department in Italy found a 
significant association between any comorbidity and both ICU 
admission and death.6 An Italian study including 2,653 cases found 
a significant association between the Charlson Comorbidity Index 
scores of 1 and death and scores of 2 and 3 or more with both 
death and hospitalisation.16 A higher score represents a greater 
level of comorbidity with 0 representing no comorbid conditions. 
 
 
3. Clinical measures 
Table 3 details clinical measures that were investigated for association with disease severity 
identified in the studies within the review. 
Table 3: Clinical measures considered for identifying symptoms of COVID-19 
Oxygen saturation  
 
Significantly 
associated with 
severe disease. 
Arterial oxygen saturation (SpO2) was reported as significantly 
associated with severe disease in four out of five studies (80%) in 
an unpublished meta-analysis including 17,648 patients with 
COVID-19, mostly in China.17 It was unclear whether this was a 
higher or lower oxygen saturation and what level was investigated.  
Saturation levels were not given, nor was it explicitly stated that 
lower oxygen saturation was associated with severe disease, this 
has been assumed. 
 
Three of the identified studies of association from settings outside 
China included oxygen saturation in their analysis. Results were 
mixed. One study examining associations in 5,279 confirmed 
cases of COVID-19 in New York found that oxygen saturation at 
levels <88% and 88–92% were associated with the risk of critical 
illness compared with levels >92% (OR 3.67, 95% CI 2.78 to 4.8 at 
<88% and OR 1.49, 95% CI 1.18 to 1.90 at 88–92%).12 A US study 
of 585 veterans aged 54–75 found that a 1% reduction in SpO2 
was not associated with hospitalisation or admission to ICU.13 The 
final study of 54 patients in California found that SpO2 was 
significantly associated with hospitalisation and development of 
pneumonia and ARDS but not admission to ICU.23 
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Respiratory rate 
 
Significantly 
associated with 
severe disease. 
Respiratory rate was reported as significantly associated with 
severe disease in six out of 10 studies (60%) in an unpublished 
meta-analysis including 17,648 patients with COVID-19, mostly in 
China.17 It is unclear what level was investigated for significance. 
 
None of the identified studies of association from settings outside 
China included respiratory rate in their analysis. 
 
Heart rate 
 
Evidence of 
association is 
unclear. 
Heart rate was reported as significantly associated with severe 
disease in one out of seven studies (14%) in an unpublished meta-
analysis including 17,648 patients with COVID-19, mostly in 
China.17 It is unclear what level of increase was investigated for 
significance. 
 
An Italian study of 2,653 cases found a small negative association 
with increased heart rate and hospitalisation but no association 
with admission to ICU.16 
 
Systolic blood 
pressure  
 
Significantly 
associated with 
severe disease. 
Systolic blood pressure (SBP) was reported as significantly 
associated with severe disease in two out of five studies (40%) in 
an unpublished meta-analysis including 17,648 patients with 
COVID-19, mostly in China.17 It is unclear whether this was higher 
or lower SBP and what level was investigated for significance. 
 
Of the identified studies of association in settings outside China, 
one US study (n=585) found that a 5 mm Hg decrease in SBP was 
associated with hospitalisation (OR 1.1, 95% CI 1 to 1.2) but not 
with ICU admission.13 
 
 
4. Method of patient consultation 
No validated method of measuring breathlessness via tele- or video consultations has been 
identified. A recommendation based on the consensus of 50 clinicians advises against using 
the Roth test.60 Questions like those in the COVID-19 Scottish Primary Care Hub Triage Guide 
can be asked. Smartphone apps should not be used as oximeters.61  
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5. Sources of further information 
For up-to-date information on signs, symptoms and prognosis of COVID-19, the following 
websites provide summaries of new evidence which are updated frequently: 
BMJ Best practice: https://bestpractice.bmj.com/topics/en-gb/3000168/prognosis and 
https://bestpractice.bmj.com/topics/en-gb/3000168/history-exam 
Centre for Evidence-Based Medicine, University of Oxford, provides rapid reviews of 
research, categorised under ‘Signs and Symptoms’, ‘Symptom Assessment’ and ‘Diagnostic 
Tests’: https://www.cebm.net/oxford-covid-19-evidence-service/ 
National Institute for Health and Care Excellence (NICE): https://www.nice.org.uk/covid-
19 
UptoDate: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-
epidemiology-virology-clinical-features-diagnosis-and-prevention#H3432457140 
 
Guidance and further information on management, care and service delivery in relation to 
COVID-19 is signposted from the Scottish Intercollegiate Guidelines Network (SIGN) website: 
www.sign.ac.uk 
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6. Methodology 
 
6.1 Key question 
This rapid review is based on a structured key question that defines the target population, the 
intervention or exposure under investigation and the outcomes used to measure efficacy, 
effectiveness, or risk. This question formed the basis of the literature search. 
In people presenting in primary care with potential COVID-19, which are the best 
predictors of adverse outcomes, such as hospitalisation and ventilation therapy? 
Population Interventions/Exposures Outcomes Notes 
 
People in the 
community 
presenting to 
primary care with 
potential COVID-
19 
 
For search 
purposes include 
all people 
presenting with 
potential 
COVID19 
including hospital-
based studies 
given lack of 
studies in the 
population of 
interest. 
 
 
 
 
 
 
Sociodemographic factors: 
age, sex, ethnicity, 
socioeconomic status. 
 
Health-related behaviours:  
smoking, alcohol intake 
 
Clinical information: 
comorbidities, current 
medications, 
previous medical history, 
BMI, 
blood pressure, 
signs on clinical examination 
(temperature, pulse, 
respiratory rate), 
onset of new symptoms (eg 
cough, temperature >37.8°C, 
fatigue, sputum, shortness of 
breath, muscle aches, sore 
throat, headache, chills, nasal 
congestion, nausea, diarrhoea) 
 
development of symptoms, 
symptom progression, 
symptom duration, 
combination of symptoms.  
 
Disease severity 
Admission to hospital 
Admission to ICU 
Mechanical 
ventilation 
Mortality 
Duration of 
symptoms  
Disease progression  
 
 
 
Consider method of 
consultation: 
telephone, video, face-
to-face and whether 
different assessments 
need to be considered 
for each. 
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6.2 Literature review 
A topic exploration was conducted to identify relevant guidance, systematic reviews and rapid 
reviews, using a broad internet search including, but not exclusively, the following websites: 
BMJ Evidence, Center for Disease Control and Prevention, Cochrane Library, Dynamed, 
MAGICApp, McMasterforum, Medrxiv, NICE, Oxford Centre for Evidence Based Medicine, 
TRIP database, Uptodate, WHO.  
A systematic search was conducted for primary sources of evidence using Medline and 
Embase. MedRXiv was searched for preprints added up to and including 24 April 2020. No 
quality assessment was carried out as all evidence is likely to be low quality given that only 
early data is available.  
6.2.1 Updates to the literature review 
A rapid scoping search was carried out between 18–23 June 2020 using BMJ Best Practice 
(https://bestpractice.bmj.com/topics/en-gb/3000168/history-exam) as the source. All 
references which were cited as preprints in the original version of this synthesis which have 
been subsequently published have been appropriately updated. 
 
6.3 Updating the review 
Scoping searches for new evidence will be conducted every two months. The review will be 
updated if new evidence emerges that changes the current conclusions.  
 
6.4 Contributors 
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 Dr David Blane General Practitioner, NHS Greater Glasgow and 
Clyde; Clinical Research Fellow in General Practice 
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 Mr Robert Heggie Research Assistant, University of Glasgow 
 Dr Bhautesh Jani General Practitioner, NHS Lanarkshire and NHS 
Greater Glasgow and Clyde; Clinical Senior Lecturer 
in Primary Care, University of Glasgow   
 Ms Joanna Kelly Senior Health Services Researcher, Healthcare 
Improvement Scotland 
 Ms Karen MacPherson Lead Health Services Researcher, Healthcare 
Improvement Scotland 
 Professor Kate O’Donnell 
 
 
Professor of Primary Care Research and 
Development, University of Glasgow 
 
 Ms Dikshyanta Rana Research Assistant, University of Glasgow 
 Ms Gaynor Rattary Guideline Coordinator, SIGN 
 Dr Carolyn Sleith Information Scientist, Healthcare Improvement 
Scotland 
 Ms Ailsa Stein Programme Manager, SIGN 
 Professor Olivia Wu Professor of Health Technology Assessment, 
University of Glasgow 
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6.5 Peer review 
General practitioners, an epidemiologist, and a lay representative were invited to comment 
on a draft version of this report, to consider the interpretation of the evidence and feasibility 
for practice.  
SIGN is grateful to these experts for their contribution. 
Dr Neave Corcoran General Practitioner, NHS Lothian 
Dr Kate Dawson General Practitioner, Benbecula Medical Practice, 
Benbecula 
Dr Ciara Drummond General Practitioner Locum, Bearsden 
Dr Robert Duncan General Practitioner, St Ronans Practice, Innerleithen 
Dr Hamish Foster MRC Clinical Research Training Fellow, University of 
Glasgow 
Dr Katie Gallacher Stroke Association Senior Clinical Lecturer, University of 
Glasgow 
Professor Phil Hannaford Professor of Primary Care, University of Aberdeen 
Dr David Hogg GP Principal, Lauderdale Medical Practice, Dunbar 
Dr Neil Houston General Practitioner, Dollar Health Centre, Dollar 
Dr Scott Jamieson General Practitioner, Kirriemuir Medical Practice, 
Kirriemuir 
Dr Carey Lunan Chair of Royal College of General Practitioners, 
Edinburgh 
Dr Frances Mair Norie Miller Professor of General Practice, University of 
Glasgow 
Dr Marianne McCallum General Practitioner, The Tannahill Surgery, Paisley 
Dr Margaret McCartney General Practitioner, Glasgow, Honorary Fellow at the 
Centre For Evidence-Based Medicine, Oxford 
Dr Paul Ryan General Practitioner, Glenmill Medical Practice, Glasgow 
 
In addition to those listed above, the following individuals provided feedback on updated 
versions of this report.  
Professor Tom Evans Professor of Molecular Microbiology, Institute of 
Infection, Immunity & Inflammation, University of 
Glasgow and Consultant Infectious Disease Physician, 
NHS Greater Glasgow & Clyde 
Ms Anne Keane Public Partner, Healthcare Improvement Scotland, 
Edinburgh 
Professor Gregory Lip Price-Evans Chair of Cardiovascular Medicine, 
University of Liverpool 
Dr Elaine McNaughton General Practitioner, Carnoustie Medical Group, 
Carnoustie 
Mr Alan Timmins Lead Clinical Pharmacist – Acute, NHS Fife 
 
6.6 Editorial review 
As a final quality check, the report was reviewed by an editorial group, as follows: 
Dr Roberta James Programme Lead, SIGN 
Dr Safia Qureshi Director of Evidence, Healthcare Improvement Scotland 
Professor Angela Timoney Chair of SIGN 
 
 
 
  
 
21 
 
Abbreviations 
ACE angiotensin-converting enzyme  
 
ARDS acute respiratory distress syndrome 
 
AT1 angiotensin-II receptor antagonists/angiotensin receptor blockers 
 
BMI body mass index 
 
CFS Clinical Frailty Scale 
 
CI confidence interval 
 
CKD chronic kidney disease 
 
COPD chronic obstructive pulmonary disease 
 
CVD cardiovascular disease 
 
HR hazard ratio 
 
ICU intensive care unit 
 
NEWS National Early Warning Score 
 
NICE National Institute for Health and Care Excellence 
 
OR odds ratio 
 
SaO2 arterial oxygen saturation 
 
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 
 
SBP systolic blood pressure 
 
SIGN Scottish Intercollegiate Guidelines Network 
 
US United States 
 
WHO World Health Organization 
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